Gund Vision Fund (formerly RD Fund)

Gund Vision Fund focuses on mission-related investments to rapidly drive research into preventions, treatments and cures for blinding retinal diseases.

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Atsena Therapeutics presented 18-month safety and efficacy results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 in patients with X-linked retinoschisis (XLRS) at the American Academy of Optometry 2026 Annual Meeting.

Read more at: https://t.co/xEU6e6Uvjo

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

José-Alain Sahel, MD, Gund Vision Fund Board Member, received the prestigious António Champalimaud Vision Award together with his colleague Botond Roska, MD, PhD, for their work to restore sight using optogenetics.

Read More at: https://t.co/4a9rgArYVT

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Beacon Therapeutics announced positive topline results for its registration-enabling VISTA trial evaluating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).

Read more at: https://t.co/KBkVkGTxWI

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

In 2018, the Retinal Degeneration Fund set out to bridge the gap between promising science and the treatments patients need.

Eight years later, that model is proven — and the vision is bigger.

Introducing the Gund Vision Fund.

https://t.co/XPFMAhgELK

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Atsena Therapeutics has announced that the European Medicines Agency (EMA) has granted orphan designation to its two clinical-stage gene therapy product candidates being developed for inherited retinal diseases.

Read more at: https://t.co/CKXxZt2VfA

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Opus Genetics has provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.

Read more at: https://t.co/WzujzlJ9JE

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Atsena Therapeutics announced the selection of a lead clinical candidate for ATSN-401, a potential best-in-class gene therapy for Stargardt disease.

Read more at: https://t.co/rm8li2XDqb

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Atsena Therapeutics has announced that the first patient has been dosed in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS).

Read more at: https://t.co/bVnE5abrhX

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

The Foundation Fighting Blindness and the RD Fund has announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic therapeutic approaches for inherited retinal diseases.

Read more about RAB and their commitment at: https://t.co/vc5ElEBbBG

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Beacon Therapeutics has announced a 12-month safety and efficacy update from its Phase 2 DAWN trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at the ARVO Annual Meeting held in Denver, Colorado.

Read more at: https://t.co/k7HvbMh9qy

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

This week, Atsena Therapeutics presented data from three studies at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, CO.

Read more at: https://t.co/cMGsmcXc9D

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Opus Genetics has announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program.

Read more at: https://t.co/UnH6iVagfx

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Atsena Therapeutics receives Data Monitoring Committee recommendation to proceed with pivotal Part C cohort of Phase 1/2/3 LIGHTHOUSE trial evaluating ATSN-201 in patients with X-linked retinoschisis (XLRS).

Read more at: https://t.co/pOygUB8Chx

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Opus Genetics solidifies leadership position in gene therapy development for inherited retinal diseases (IRDs) with strategic long-term financing by Oberland Capital. Read more at https://t.co/0ojJq0K7hq

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

RD Fund portfolio company Opus Genetics reports encouraging Phase 1/2 OPGx-BEST1 data: well tolerated, 12-letter visual acuity gain, 23% reduction in central retinal thickness. Full Cohort 1 results expected mid-2026. https://t.co/BZmxKKjzdZ

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

The RD Fund community mourns the loss of Karen Petrou, Foundation Fighting Blindness Board Chair and RD Fund Vice Chair, who passed away after a private battle with liver cancer.

Read more about Karen’s legacy on our website: https://t.co/CGVY4BoVRx

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

RD Fund portfolio company @SparingVision has completed patient dosing in its Phase I/II PRODYGY trial of SPVN06 for retinitis pigmentosa.

This milestone advances the program toward a 2027 data readout. https://t.co/dUImJ6RsuA

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

#GeneTherapy milestone 🧬 Opus Genetics, founded by the RD Fund, has launched a clinical trial for MERTK-related retinitis pigmentosa, a rare inherited retinal disease with no approved treatments. https://t.co/u8yTA4bOLG

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Congratulations to RD Fund portfolio company @AtsenaThera on their manufacturing partnership with Genezen! This collaboration supports the pivotal LIGHTHOUSE study for XLRS gene therapy ATSN-201, on track for potential BLA filing in 2028. Learn more at https://t.co/5b3eCDmNGx

[Gund Vision Fund (formerly RD Fund) @GundVisionFund]

Proud to join leading investors in supporting @BeaconTx_'s $75M Series C financing, advancing gene therapies like laru-zova for X-linked retinitis pigmentosa and expanding its pipeline for blinding diseases.

Read more: https://t.co/1iTg3ldtVu

#GeneTherapy #XLRP #RDFund